Theravance Biopharma (TBPH) EBIT Growth (3y) (2016 - 2026)
Theravance Biopharma (TBPH) EBIT Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 79.65% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 27.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.53% |
| Dec 31, 2025 | 46.56% |
| Sep 30, 2025 | 10.96% |
| Jun 30, 2025 | 53.37% |
| Mar 31, 2025 | 27.89% |
| Dec 31, 2024 | 45.29% |
| Sep 30, 2024 | 41.31% |
| Jun 30, 2024 | 37.43% |
| Mar 31, 2024 | 48.88% |
| Dec 31, 2023 | 56.63% |
| Sep 30, 2023 | 51.46% |
| Jun 30, 2023 | 39.32% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | 37.26% |
| Sep 30, 2022 | 48.05% |
| Jun 30, 2022 | 14.15% |
| Mar 31, 2022 | 19.45% |
| Dec 31, 2021 | 3.56% |
| Sep 30, 2021 | 4.96% |
| Jun 30, 2021 | -9.59% |